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Distinct mesenchymal progenitor cell subsets in the adult human
synovium
Abstract
Objective. To analyse the heterogeneity at the single-cell level of human mesenchymal progenitor cells
from SM. Methods. Cell populations were enzymatically released from the knee joint synovium of adult
human individuals. Single cell-derived clonal populations were obtained by limiting dilution and serially
passaged to determine growth rates. Phenotypic analysis was carried out by flow cytometry. Replicative
senescence was assessed by the senescence-associated beta-galactosidase staining. Telomere lengths
were determined semiquantitatively by Southern blotting. Telomerase activity was measured using a
real-time quantitative telomerase repeat amplification procedure. Culture-expanded clonal populations
were subjected to in vitro differentiation assays to investigate their mesenchymal multipotency. Results.
The 50 clones analysed displayed wide variations in the proliferation rates, even within the same donor
sample. The time taken to reach 20 population doublings ranged from 44 to 130 days. The phenotype of
the clones tested was compatible with that of mesenchymal stem cells. Mean telomere lengths ranged
from 5.2 to 10.9 kb with positive linear trend with telomerase activity, but no correlation with
proliferative rates or cell senescence. All clones tested were capable of chondrogenic and osteogenic
differentiation, though with large variability in potency. In contrast, only 30% of the clones were
adipogenic. Conclusions. We report for the first time the co-existence, within the synovium, of
progenitor cell subsets with distinct mesenchymal differentiation potency. Our findings further
emphasize the need for strategies to purify cell populations with the clinically desired tissue formation
potentials.
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ABSTRACT 
Objective: To analyze the heterogeneity at the single cell level of mesenchymal stem 
cells (MSCs) from synovial membrane. 
Methods: Cell populations were enzymatically released from the knee joint synovium 
of adult human individuals. Single-cell-derived clonal populations were obtained by limiting 
dilution and culture expanded by serial passaging to determine growth rates. Phenotypic 
analysis was carried out by fluorescence-activated cell sorting (FACS). Telomere lengths 
were determined semiquantitatively by Southern blotting. Telomerase activity was measured 
using a real-time quantitative telomerase repeat amplification procedure. Culture expanded 
clonal populations were subjected to standard in vitro assays to investigate their 
mesenchymal multipotency. Upon treatments, phenotypes of cell cultures were analyzed by 
histochemistry. Chondrogenesis was assessed by staining micromass cultures with alcian blue 
and measuring absorbance of the extracted dye. Osteogenesis was assessed quantitatively by 
measurements of calcium deposits. Adipogenesis was assessed by staining with oil red O. 
Results: There was a wide variation in the proliferation rates between the clones, even 
within the same donor sample. The time taken to reach 20 population doublings ranged from 
45 days to 130 days. The phenotype of all clones tested was compatible with that of MSCs. 
Clonal populations displayed relatively long telomeres with significant correlation with the 
telomerase activity, but not with cell senescence. All clones tested were chondro-osteogenic, 
though with variable potency, while 30% of the clones were adipogenic. No correlation was 
found between the variables tested and the differentiation potency of clonal populations. 
Conclusion: We report for the first time the coexistence of cell subsets with distinct 
differentiation abilities in the synovial membrane. Our findings further emphasize the need 
for strategies to purify cell populations with the clinically desired tissue formation potentials. 
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Abbreviations: EDTA ethylenediaminetetraaceticacid, EGTA ethylene glycol 
tetraacetic acid , CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate, 
PMSF phenylmethanesulphonylfluoride, SYBR [2-[N-(3-dimethylaminopropyl)-N-
propylamino]-4-[2,3-dihydro-3-methyl-(benzo-1,3-thiazol-2-yl)-methylidene]-1-phenyl-
quinolinium].
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INTRODUCTION 
Mesenchymal stem cells (MSCs) are clonogenic undifferentiated cells capable of both 
self-renewal and differentiation into lineages of mesenchymal tissues, including cartilage, 
bone, adipose tissue, and skeletal muscle. The “conventional” MSCs are those obtained from 
bone marrow. However, MSCs have been isolated from several other tissues, including the 
synovial membrane (SM) 1 and synovial fluid 2, periosteum 3, 4, skeletal muscle 5, adipose 
tissue 6, and articular cartilage 7 8, 9. In view of their presence in many easily-accessible adult 
tissues and their abilities to differentiate into multiple lineages, MSCs are excellent 
candidates to be used for skeletal tissue repair in regenerative medicine. 
Increasing evidence supports the use of stem cells in the clinic. A major concern is the large 
structural and clinical variability in outcome. Such variability is at least partly due to donor-
related factors and the inconsistency of stem cell preparations, as highlighted by the report of 
contrasting results in clinical trials of cardiac cell therapy 10. 
We reported the isolation and characterization of multipotent MSCs from adult human 
synovial membrane (SM-MSCs) 1. These cells were derived from mixed unselected 
populations of adherent synovial cells following in vitro expansion. SM-MSCs could be 
expanded for up to at least 30 population doublings with limited senescence and maintenance 
of multilineage differentiation capacity. In an in vivo mouse model of muscle injury and 
regeneration, human SM-MSCs were shown to contribute to the satellite cell compartment 
and to myofibers, while in another study they formed bone 11, 12. 
Human SM-MSCs, like the bone marrow counterparts, appear heterogenous in their 
growth and differentiation abilities. Mixed cells are likely to produce an unpredictable 
biological activity when used in the clinic. So far, there has been no study aiming at a full 
characterization of human SM-MSCs at the single cell level. Such characterization could help 
the biomedical community to devise novel strategies for purification of cell subsets with a 
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consistent and predictable biological activity and potency. The strategy for obtaining cell 
populations with predictable tissue formation capacity would be at least partly dependent on 
the presence of either multiple functionally distinct cell subsets or more primitive stem cells 
capable of multilineage differentiation. 
In the present study, we analyzed human SM-MSCs at the single cell level by 
studying clonal cell populations derived by limiting dilution. We confirm wide variations in 
growth and differentiation potentials between clones even within the same donor sample, and 
report for the first time the coexistence of progenitors with different mesenchymal 
differentiation potency. 
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MATERIALS AND METHODS 
Harvest of synovial membrane and isolation of cells. Synovial membrane was 
collected aseptically, after informed consent, from the knee joints of six human donors (Table 
1). Three donors had a history of osteoarthritis and underwent total knee replacement, while 
the remaining three had no history of knee joint disorders and did not have active infections 
or tumors, and therefore were referred to as normal. 
SM samples were rinsed twice with Hanks’ balanced salt solution (HBSS; Invitrogen) 
supplemented with 2x antibiotic-antimycotic solution (100 units/ml penicillin, 100 µg/ml 
streptomycin, and 0.25 µg/ml amphotericin B; Invitrogen), finely minced, and digested with 
0.2% w/v collagenase type IV (Invitrogen) in growth medium consisting of high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM; Lonza) supplemented with 10% fetal bovine 
serum (FBS; Invitrogen) and antibiotics. Following overnight incubation at 37°C, cells were 
collected by centrifugation, washed twice with Ca++/Mg++-free  phosphate buffered saline 
(PBS; Lonza), further digested for 5 minutes at 37°C using Trypsin-EDTA (0.25% Trypsin, 
1mM EDTA; Invitrogen), washed again with growth medium, and filtered through a 70 µm 
cell strainer (Marathon Laboratory). Red blood cells were lysed. Cells were then counted 
using trypan blue (Sigma) to assess cell viability and were either culture expanded or used to 
generate clonal populations by limiting dilution as described below. 
Cloning and culture expansion of synovial cells. Cell cloning was performed by 
limiting dilution. Freshly isolated or cultured cells were suspended in growth medium and 
plated at a density of 0.3 viable cells/well in 96-well, flat-bottomed culture plates. Four plates 
were used for each donor sample. At 30 days, aggregates of >32 cells were scored as clones. 
Thirty-two cells were chosen as this represents a population of cells derived from more than 5 
population doublings of a single cell, thereby discounting a transit-amplifying cell 13. Up to 
ten clones per donor sample were selected. Cells were culture expanded in monolayer in 
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growth medium at 37ºC in a humidified atmosphere of 5% CO2. The medium was replaced 
every 3 days. Clonal cell populations were subcultured upon reaching confluence with serial 
1:4 dilution passages. For each clone, aliquots were cryopreserved. 
Kinetics of growth. Cells of each clone were plated at a density of 3,000 cells/cm2 in 
6-well tissue culture plates and were continuously passaged in 6-well plates at the same 
density whenever they reached sub-confluence. The remaining cells of each passage were 
cryopreserved. The number of viable cells per ml was determined at each passage using a 
hemocytometer. The growth rate of each clone was expressed as number of population 
doublings (PDs) during time (days), and it was determined at each passage. A graph was 
plotted against duration in culture for a single cell to undergo 20 PDs. 
Senescence-associated β-galactosidase staining (SA-β-gal). SA-β-gal staining was 
performed as described 14. Cells were plated in chamber slides and allowed to attach in 
growth medium. The day after, cells were washed in PBS, fixed in 4% paraformaldehyde 
(PFA), washed, and incubated overnight in a humid chamber at 37°C with fresh β-gal 
staining solution (1 mg/ml X-Gal, 40 mM citric acid/sodium phosphate [pH 6.0], 5 mM 
potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2). 
Cells were then washed twice with PBS, counterstained with Neutral Red (1% in water) and 
mounted with DEPEX. Human Embryonic Kidney (HEK) 293 cells and early passage (P4-
P5) SM-MSCs were used as a negative control. Late passage (P18) SM-MSCs cells and 
senescent human dermal fibroblasts were used as a positive control. 
Osteogenesis assay. The in vitro osteogenesis assay was performed as described 
previously 1. Calcium content was determined at 3 weeks of treatment with osteogenic 
medium and normalized to protein content as described previously 12. Briefly, cell layers were 
rinsed twice with PBS and scraped off the dish in 0.5N HCl. The cell layers were extracted 
by shaking for 4 hours at 4°C, were centrifuged at 1,000g for 5 minutes, and the supernatant 
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was used for colorimetric calcium determination using a commercially available kit, 
according to the recommendations of the manufacturer (Thermo Electron Corporation). Each 
clone was plated in triplicate. Total calcium was calculated from standard solutions and 
expressed as micrograms per microgram of protein content. Protein content was determined 
in parallel wells by the bicinchoninic acid protein assay (Sigma), using bovine serum albumin 
(Sigma) as standard. 
To stain calcium deposits, cells were rinsed twice with PBS, fixed with 4% PFA, and 
covered with alizarin red S solution (2% aqueous solution [pH 4.2]; Sigma) for 3 minutes. 
Cultures were then washed thoroughly with distilled water. 
Chondrogenesis assay. The in vitro chondrogenesis assay was performed in 
duplicate by combining micromass culture and treatment with 10 ng/ml of transforming 
growth factor β1 (TGFβ1; Biosource) in a serum-free medium. Micromass cultures were 
obtained by pipetting 20-µl droplets of cell suspension at a density of 2.0 x 107 viable cells/ml 
into individual wells of 24-well plates. After cells were allowed to attach without medium for 
3 hours, a serum-free medium consisting of high glucose DMEM supplemented with 50 
µg/ml ascorbic acid, ITS+ and 100nM dexamethasone (all from Sigma) was added. The day 
of plating in micromass culture was designated as day 0. Starting on day 1, when the culture 
medium was changed, TGFβ1 was added to the culture medium every other day, at a final 
concentration of 10 ng/ml. 
After 6 days, cultures were rinsed twice with PBS, fixed with methanol for 30 minutes 
at -20°C, washed with distilled water, and covered with alcian blue at pH 0.2 (0.5% alcian 
blue 8 GS [Carl Roth, Karlsruhe, Germany] in 1N HCl). After overnight staining, cultures 
were washed extensively with distilled water. For quantitative analyses, alcian blue-stained 
cultures were extracted with 200 µl of 6M guanidine HCl in Milli-Q water for 6 hours at 
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room temperature. The absorbance of the extracted dye was measured at 630 nm by 
spectophotometry. 
Adipogenesis assay. The in vitro adipogenesis assay was performed as described 15. 
One hundred cells were plated in 60cm2 cell culture dishes and allowed to grow for two 
weeks. The medium of the treated samples was then replaced with Adipogenic Induction 
medium (AI), consisting of growth medium supplemented with 1µM dexamethasone, 0.5mM 
3-isobutyl-1-methyl-xanthine, 10µg/ml insulin, and 100µM indomethacin (all from SIGMA). 
After 72 hours, the AI medium was replaced with Adipogenic Maintenance medium (AM), 
consisting of growth medium supplemented with 10µg/ml insulin. After 24 hours, the AM 
was discarded and cells received two more treatments with alternating AI – AM. By the end 
of the third treatment, the cells were maintained in AM for a total of 21 days from the 
beginning of the adipogenesis assay treatment. Cells were then washed with PBS, fixed with 
4% PFA, washed with water, rinsed with 60% isopropanol, stained with Oil Red O solution 
(0.1% Oil Red O [SIGMA] in 60% isopropanol), rinsed again with 60% isopropanol, and 
washed extensively with water. The total number of colonies was determined after 
counterstaining with crystal violet (0.5%w/v in methanol). 
Telomere length assay. Genomic DNA was extracted from clonal cell monolayers 
using one-step lysis and DNA exclusion columns (Nexttec) and the amount quantified 
fluorescently using picogreen (Molecular Probes). Telomere lengths were determined semi-
quantitatively by Southern blotting using TeloTAGGG telomere length assay, according to 
the recommendations of the manufacturer (Roche). Mean telomere lengths were determined 
by densitometric scanning of exposed X-ray film. 
Telomerase activity. Comparative analysis of telomerase activity in clonal cell 
populations was performed using a real-time quantitative telomerase repeat amplification 
procedure (RTQ-TRAP) as previously described 16. Cell extracts were obtained by adding 
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200µl of lysis buffer per 1x106 cells (lysis buffer; 10 mM Tris pH 8.3, 1.5 mM MgCl2, 1 mM 
EGTA, 10% glycerol, 0.5% CHAPS buffer, 1 mM PMSF, 5mM β-mercaptoethanol and 
200U RNAsin). Each RTQ-TRAP reaction was composed of 1xSYBR Green Mastermix 
(Eurogentec Ltd.), 10 mM EGTA, 0.2µg T4 gene protein, 0.3µM primers TS (5’-AAT CCG 
TCG AGC AGA GTT-3’) and ACX (5’-GCG CGG [CTT ACC]3 CTA ACC-3’) and 25 x 103 
cell extract in a final volume of 25µl. The reaction mixture was incubated at 25°C for 20 
minutes to allow TS primer extension by telomerase, heated to 95°C for 10 minutes to 
activate Taq Polymerase, followed by 40 cycles at 95°C for 20 seconds, 50°C for 30 seconds 
and 72°C for 90 seconds. Telomerase activity in cell samples was calculated based on the 
threshold cycle (CT). All samples were run in triplicate and lysis buffer was used as a 
negative control. Immortal human leukaemia cell line 60 (HL60) was used as a positive 
control for telomerase activity. HL60 cell extracts were serially diluted and assayed by RTQ-
TRAP to generate a standard curve that was used to derive telomerase activity units based on 
the number of input cell equivalents. 
Phenotyping of culture-expanded clonal cell populations using 3-color flow 
cytometry. Culture expanded clonal cell populations were used for flow cytometry at 105 
cells/test. Phycoerythrin (PE)-conjugated antibodies were: CD166 and CD73 (from 
Pharmingen), CD105 and CD90 (Serotec) and SSEA-4 (R&D Systems). FITC-conjugated 
antibodies were: CD45 (DAKO), CD13, and CD31 (Serotec), CD81 (Pharmingen) and 
CD271 (Miltenyi Biotec). Isotype-specific negative control antibodies were purchased from 
Serotec. Data were acquired using BD FACScan and dead cells were gated out based on 
propidium iodide exclusion (Sigma). All flow cytometry data were analysed with WinMDI 
v8 (Scripps Research Institute, La Jolla, CA). 
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Statistical analysis. All data are presented as mean ± standard deviation (SD). Each 
assessment was performed on 2 or 3 cultures per clonal cell population. Pearson’s product-
moment correlation coefficient r was calculated in order to assess the linear associations 
between variables. Correlations were considered to be significant at p <0.05. 
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RESULTS 
Growth potential of clonal populations. We first analyzed the proliferative capacity 
of single-cell-derived clonal populations. Clonal populations were derived by limiting 
dilution in 96-well plates. Four plates were set up for each of the 6 individual donor samples. 
A total of 50 single-cell-derived clonal populations were randomly selected (see Table 1 for 
details). The growth curves of the clones tested are shown in Supplementary Figure 1. Out of 
the 50 clones selected, 3 clones stopped growing at 17-18 PDs and 7 clones reached 25 PDs. 
Twenty five clones grew beyond 30-35 PDs, 12 clones reached 40 PDs, 2 clones exceeded 45 
PDs, and one clone (A9) grew beyond 50 PDs.  
The proliferative capacities of the individual clones were assessed according to the 
time taken by a single cell to undergo 20 PDs. A wide variation in the proliferation rates was 
observed between the clones, even within the same donor sample. The time taken to reach 20 
PDs ranged from 45 days to 130 days (Figure 1). The individual clones obtained from donor 
sample B were growing faster and displayed less variation in their proliferative capacities 
than the clones of the other samples tested. 
Phenotype. To evaluate the phenotype of the expanded clonal cells, we performed 
fluorescence-activated cell sorting analysis, testing 5 representative clones (A2, A8, D1, D3 
and E10) for the expression of a marker set associated with multipotent MSCs 3, 12, 17(Figure 
2). All clones tested were negative for the hematopoietic lineage cell marker CD45 and the 
endothelial cell marker CD31, both known to be not expressed by MSCs 17. CD271/LNGFR 
was also undetectable, as reported with culture expanded non-clonal MSC populations 12, 18. 
Clones displayed variable expression of the MSC positive markers CD13, CD105, CD73, 
CD166, SSEA4, CD81 and CD90. These data indicate that the clonal cells tested display a 
phenotype compatible with culture expanded MSCs. 
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Replicative senescence, telomere lengths and telomerase activity. MSCs are 
somatic cells that display a long-term self-renewal capacity in vitro that is dependent upon 
factors such as replicative senescence, telomere lengths and telomerase activity. We first 
investigated the occurrence of cell senescence by assessing, during clonal culture expansion, 
the SA-β-gal, an assay that detects the presence of the β-galactosidase enzyme expressed by 
senescent cells. For this assay, we selected clones of donor sample A, which were 
heterogeneous in their proliferative capacity, and clones of donor sample B, which instead 
displayed similar and overlapping growth curves (Supplementary Figure 1). An increase in 
the proportion of senescent cells during the time in culture was observed in most of the clones 
(Figure 3A and B), though with variability across the clones tested. Cells at PD18 were 
mostly negative and had a fibroblast-like morphology, whereas after 35 PDs cells stained 
very intensely and were morphologically flat and bigger in size (Figure 3A), a feature 
consistent with the senescent phenotype. 
We then measured telomere lengths and telomerase activity in 11 clonal populations 
after a number of PDs ranging between 23 and 49. Despite the extensive expansion in culture, 
all clones displayed relatively long telomeres, ranging from 5 Kb (C6) to 10 Kb (A5 – Figure 
4A). Telomerase activity, determined as the equivalence of each clone to HL60 cell line 
(AV/HL60), was between 0.0734 (B3) and 1.024 (E10). Importantly, telomere length and 
telomerase activity were significantly correlated with each other (Figure 4B), whilst they 
correlated neither with replicative senescence nor with the overall number of PDs or the 
duration of a PD at the time of their measurements. 
Differentiation potential of clonal populations. A total of 21 clones were tested for 
their ability to differentiate towards mesenchymal lineages using well established in vitro 
assays (Figure 5). These assays were performed after a similar number of PDs (between 22 
and 30, with the exception of clone A8 that was assessed after 47 PDs). There was 
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considerable variation in the extent of differentiation between the clonal populations tested 
with no correlation with the PDs. 
All clones tested were chondrogenic as determined by alcian blue staining of TGF-β1 
treated micromasses, with a range of absorbance values between 0.2 and 0.4. One clone, D1, 
was highly chondrogenic with an absorbance of 0.75. Untreated clones were negative (Figure 
5A). 
All clones responded to osteogenic treatment in monolayers as assessed by alizarin 
red staining for calcium. For quantitation, we measured calcium deposition, which we 
recently reported to be significantly correlated with the amount of ectopic bone formation in 
vivo following subcutaneous transplantation of human MSC-seeded scaffolds in nude mice 12. 
Under our conditions, untreated clones did not show any calcium deposition. By contrast, 
treated clones responded with deposition of calcium ranging from 0.5 and 4 µg of calcium per 
µg of proteins (Figure 5B). 
Adipogenic differentiation was assessed by Oil Red O staining. Seven out of the 21 
clones tested generated colonies of adipocytes, which stained with oil red O (Figure 5C). The 
rate of oil red O-positive colonies varied between 1.6 % (B6) and 38 % (E4 – Figure 5C). 
Under our experimental conditions, the differentiation potential of the tested clonal 
populations did not correlate with number of PDs, replicative senescence, telomere length or 
telomerase activity. 
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DISCUSSION 
Several studies indicate the therapeutic utility of MSCs in humans 19-25 However, 
inconsistency of MSC preparations limits standardization. To develop standard protocols for 
an autologous cell transplant with the prospect to be used routinely in the clinic, a 
requirement is the obtainment of a sufficient number of well-defined MSCs, which should 
possess fundamental characteristics such as proliferative capacity as well as known potency 
with related ability to deposit the required matrix proteins. We previously reported that SM-
MSCs possess high self-renewal capacity and a multipotency that is inherent to the single cell 
1. Here, we attempted to better characterize SM-MSCs by studying them at the single-cell 
level, using clonal populations obtained by limiting dilution, with a goal of discerning 
multipotent stem cell pools from progenitor cell populations with more restricted potency. 
Such information is clinically relevant for the standardization of tissue engineering 
applications employing human SM-MSCs. 
It is known from previous studies that single-cell-derived clonal MSC populations 
become heterogeneous during culture expansion 12, 26, 27. The phenotypic heterogeneity within 
each clonal population may be due to the different status of the individual cells of the single-
cell progeny (e.g., different phases of cell cycle, symmetric or asymmetric cell division, 
different stages of differentiation). Nonetheless, we opted to study in depth clonal populations 
since the cells within a single-cell-cloned population are genetically and perhaps 
epigenetically homogeneous, which would explain why clonal cells maintain in culture a 
certain degree of functional consistency 12. 
We analyzed up to 10 clones per donor sample. As expected and in keeping with our 
previous study 12, wide variations in the proliferation rates were observed between clones, 
even within clones from the same donor sample. This suggests that our plastic adherent non-
clonal MSCs does not consist of a uniform population of stem cells. It is worth to mention 
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that not all of the clones were expandable under our tissue culture conditions, with 3 of the 50 
clones tested unable to grow beyond 20 PDs. 
A factor accounting for the growth heterogeneity could be cell senescence, a common 
phenomenon occurring to various degrees in somatic cells during in vitro culture expansion. 
As expected, we observed generally an increase in SA-β-Gal positive cells as PDs increased. 
Highly expressing SA-β-Gal cells were more enlarged and flatter in morphology, compatible 
with a senescent phenotype. Interestingly, the percentage of senescent cells in some clones 
appeared to decrease and then to increase again, rather than to continuously increase as the 
cells were expanded. This could simply be due to a certain degree of variability in the assay. 
However, during passaging senescent cells might be left behind, thus selecting for non-
senescent cells. In addition, there is evidence that replicative senescence may not be 
irreversible as some senescent cells can, under specific conditions, recover from growth 
arrest, re-enter the cell cycle, and replicate their DNA 30, 31.  
Although the phenomenon of senescence is not fully understood, it is believed that 
rather than being the result of cell ageing, it is more likely to be a protective mechanism, not 
necessarily irreversible, activated by normal cells in response to various types of stress such 
as carcinogenesis 28. Indeed, unlike embryonic stem cells, MSCs do not form tumors when 
injected into mice 29, a property that would favor their use in cell based therapies. 
Telomere elongation by telomerase is thought to be necessary to guarantee a high 
number of cell divisions 32. The high self-renewal capacity of the synovial clonal populations 
is substantiated by our finding of relatively long telomeres in clonal populations even after a 
high number of PDs. Notably, a significant correlation was found between telomerase activity 
and telomere length, supporting the accuracy of our experiments. The entity of cell 
senescence, known to be related to telomere shortening 33, was minimal at early PDs but 
increased throughout culture expansion. Nonetheless, under our experimental conditions we 
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did not find any correlation between replicative senescence and telomere lengths or 
telomerase activity. 
Variations in the growth potential of clonal populations could be due to the 
coexistence of multiple cell types selected by plastic adherence and grown under our culture 
conditions. We previously reported that SM-MSCs are multipotential with a single-cell-
inherent ability to differentiate down the chondrogenic, osteogenic and adipogenic pathways 
in vitro, when using a total of 5 clones 1. In the present study we tested 21 clones from 6 
donor samples and observed that all clonal populations were chondro-osteogenic whilst 7 of 
the 21 clones were adipogenic under our experimental conditions. When the same in vitro 
cell differentiation assays were performed using parental cells (i.e. mixed non-clonal cell 
populations), the donor samples were tripotential (data not shown). Altogether, our findings 
suggest the coexistence in the synovial membrane of progenitor cell subsets with distinct 
differentiation abilities. It has to be noted, however, that in order to characterize single-cell 
clonal populations high numbers of cells are required to perform all the tests described in this 
study. The extensive culture expansion may have caused loss of adipogenic potential that was 
originally present in these cells, as has been suggested for bone marrow-derived MSCs 34. It is 
thus possible that some synovial clones retained their multipotentiality through a high number 
of PDs, whereas others lost the ability to form adipocytes, whilst retaining chondro-
osteogenic capacity. 
To our knowledge, this is the first study to report the existence of single-cell-derived 
clonal populations in the synovial membrane that are chondro-osteogenic but unable to 
differentiate into adipocytes. As reported with bone marrow MSCs 34, we did not observe 
clones with a differentiation potential restricted to the osteo-adipogenic or to the chondro-
adipogenic phenotype. 
 18 
In a previous study with bone marrow derived MSC clonal populations 35, wide 
variations were observed in clonal cell replication that were directly related to the clonal 
differentiation potentials. In our study, we did not observe any correlation between any 
feature of growth rate and the clonal differentiation potential. Altogether, these findings 
indicate the importance of developing protocols for purification of cells that display 
functional homogeneity and predictable biological behavior for cell-based therapy. In our 
study, clones expressed the putative MSC markers, but the markers tested did not correlate 
with the differentiation potential. This would emphasize the need to investigate for novel 
characteristic cell-surface markers of MSCs that would be linked to specific biological 
behaviors and could therefore be used as quality controls in the cell manufacturing process. 
The generation of consistent MSC-based therapeutic protocols is a prerequisite to 
translating stem cell technologies into routine clinical application. We do not advocate the 
use of clonal populations in the clinic, as this would be impractical and costly. However, 
studies of clonal populations will help in the identification of marker sets for prospective 
purification of MSC subpopulations, functionally homogeneous in their clinically preferred 
differentiation capacities. Such purification will increase the consistency of MSC 
preparations for clinical use, thus allowing standardization of therapeutic protocols 
employing MSCs. 
 19 
 
ACKNOWLEDGMENTS 
This study was supported by MRC grant G108/620. Professor De Bari is a Fellow of 
the Medical Research Council, UK. Dr Dell’Accio is a Fellow of the Arthritis Research 
Campaign, UK. 
 
 
 
 20 
References 
1. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells 
from adult human synovial membrane. 2001.  
2. Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P, et al. Enumeration 
and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor 
cells in inflammatory and degenerative arthritis. 2004.  
3. De Bari C, Dell'Accio F, Vanlauwe J, Eyckmans J, Khan IM, Archer CW, et al. 
Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell 
lineage analysis. 2006.  
4. Nakahara H, Bruder SP, Haynesworth SE, Holecek JJ, Baber MA, Goldberg VM, et al. 
Bone and cartilage formation in diffusion chambers by subcultured cells derived from the 
periosteum. 1990.  
5. Asakura A, Komaki M, Rudnicki M. Muscle satellite cells are multipotential stem cells 
that exhibit myogenic, osteogenic, and adipogenic differentiation. 2001.  
6. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from 
human adipose tissue: implications for cell-based therapies. 2001.  
7. Dell'Accio F, De Bari C, Luyten FP. Microenvironment and phenotypic stability specify 
tissue formation by human articular cartilage-derived cells in vivo. 2003.  
8. Alsalameh S, Amin R, Gemba T, Lotz M. Identification of mesenchymal progenitor cells 
in normal and osteoarthritic human articular cartilage. 2004.  
 21 
9. Dowthwaite GP, Bishop JC, Redman SN, Khan IM, Rooney P, Evans DJ, et al. The 
surface of articular cartilage contains a progenitor cell population. 2004.  
10. Rosenzweig A. Cardiac cell therapy--mixed results from mixed cells. 2006.  
11. De Bari C, Dell'Accio F, Vandenabeele F, Vermeesch JR, Raymackers JM, Luyten FP. 
Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. 
2003.  
12. De Bari C, Dell'Accio F, Karystinou A, Guillot PV, Fisk NM, Jones EA, et al. A 
biomarker-based mathematical model to predict bone-forming potency of human synovial 
and periosteal mesenchymal stem cells. 2008.  
13. Jones PH and Watt FM. Separation of human epidermal stem cells from transit 
amplifying cells on the basis of differences in integrin function and expression. 1993.  
14. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that 
identifies senescent human cells in culture and in aging skin in vivo. 1995.  
15. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived 
from various mesenchymal tissues: superiority of synovium as a cell source. 2005.  
16. Hou M, Xu D, Bjorkholm M, Gruber A. Real-time quantitative telomeric repeat 
amplification protocol assay for the detection of telomerase activity. 2001.  
17. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. 
Multilineage potential of adult human mesenchymal stem cells. 1999.  
 22 
18. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al. Isolation 
and characterization of bone marrow multipotential mesenchymal progenitor cells. 2002.  
19. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, et 
al. Repair of large bone defects with the use of autologous bone marrow stromal cells. 2001.  
20. Vacanti CA, Bonassar LJ, Vacanti MP, Shufflebarger J. Replacement of an avulsed 
phalanx with tissue-engineered bone. 2001.  
21. Warnke PH, Springer IN, Wiltfang J, Acil Y, Eufinger H, Wehmoller M, et al. Growth 
and transplantation of a custom vascularised bone graft in a man. 2004.  
22. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous 
bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects 
in human patellae: two case reports. 2004.  
23. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous 
culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage 
defects in osteoarthritic knees. Copyright 2002 OsteoArthritis Research Society International. 
2002.  
24. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated 
allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children 
with osteogenesis imperfecta: Implications for cell therapy of bone. 2002.  
25. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. 
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in 
children with osteogenesis imperfecta. 1999.  
 23 
26. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem 
cells in cultures of plastic-adherent cells from human bone marrow. 2000.  
27. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-
renewing and multipotential adult stem cells in colonies of human marrow stromal cells. 
2001.  
28. Ben-Porath I and Weinberg RA. The signals and pathways activating cellular senescence. 
2005.  
29. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative 
senescence of mesenchymal stem cells: a continuous and organized process. 2008.  
30. Blank M and Shiloh Y. Programs for cell death: apoptosis is only one way to go. 2007.  
31. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, et al. INK4a-deficient 
human diploid fibroblasts are resistant to RAS-induced senescence. 2002.  
32. Aubert G and Lansdorp PM. Telomeres and aging. 2008.  
33. Blasco MA, Gasser SM, Lingner J. Telomeres and telomerase. 1999.  
34. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone 
marrow differentiate in vitro according to a hierarchical model. 2000.  
35. Mareddy S, Crawford R, Brooke G, Xiao Y. Clonal isolation and characterization of bone 
marrow stromal cells from patients with osteoarthritis. 2007.  
 24 
Table 1. Synovial tissue specimens used in the study. 
M = male, F = female, N = normal (donors had no history of knee joint disorders and 
did not have active infections or tumors), OA = osteoarthritis, P = number of passage of 
parental cells, from which clones were derived by limiting dilution. 
 
 
 
 
 
 
 
 
 
 
 
 
Donor Age 
(yrs) 
Sex Clinical 
history 
No. of 
clones 
Passage 
A 55 M N  7 Fresh 
B 74 F OA 6 P6 
C 58 F N 9 P7 
D 73 F OA 8 Fresh 
E 90 F N  10 Fresh 
F 74 F OA 10 P1 
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FIGURE LEGENDS 
 
Figure 1. Proliferation rates of individual clones to undergo 20 PDs. Each bar represents 
the time needed for each clone to reach 20 population doublings. Stripped bars indicate the 
clones that were tested for cell differentiation assays. The clones that were further analyzed 
for telomere lengths, telomerase activity and the presence of MSC markers by FACS, are 
labeled accordingly (T = Telomere length assay, telomerase activity). Not shown in the 
graphs are clones C7, D9 and F4, which stopped growing before 20 PDs (at 17, 17, and 18 
PDs, respectively). 
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Figure 2. Surface marker phenotype of synovial clonal cells following culture expansion. 
Results from a representative clone (A8) are shown. For each marker tested, the percentage of 
positive cells is expressed as the mean ± SD of 5 clones. Solid histograms show marker 
expression; open histograms show negative isotype controls. Horizontal line shows positive 
cells. 
 
 27 
 
 
 
Figure 3. Senescence-associated β-galactosidase activity. A. SA-β-gal staining of a fast-
growing clone (A5) and a slow-growing clone (A6) throughout culture expansion. Aa and Ab 
show clone A5 after 18 PD (54 days) and 35 PDs (144 days), respectively; Ac and Ad show 
clone A6 after 19 PDs (54 days) and 30 PDs (171 days), respectively. Senescent cells appear 
blue. Counterstaining is with neutral red. Scale bar = 50 µm. B. Percentage of senescent cells 
in clones selected from samples A and B, at 18 PDs, 25 PDs and 35 PDs. Results indicate a 
trend in progressive increase in replicative senescence paralleling the increase in PDs. 
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Figure 4. Telomere length and telomerase activity. A. Southern blotting for telomeres. 
Eleven culture-expanded clonal populations from 5 donors (as indicated) were analyzed by 
Southern blotting for the length of their telomeres. Note the apparent gaps in the DNA 
streaks, which confirm the purity of single-cell-derived clonal populations. The mean 
telomere length of each clone is indicated in Kb. The U937 cell line was used as a positive 
control (high molecular weight [HMW]; mean telomere length 10.2 kb), and the HL-60 cell 
line was used as a negative control (low molecular weight [LMW]; mean telomere length 3.9 
Kb. B. Plot of average telomere length (Kb) versus telomerase activity, expressed in arbitrary 
units (ratio of the clonal cell equivalents divided by the HL60 cell equivalent at 25K cells). r 
= 0.396, p<0.05. 
 
 
 29 
 
Figure 5. In vitro mesenchymal differentiation assays. Twenty one culture expanded 
single-cell-derived clonal populations were subjected to differentiation assays. A. 
Chondrogenic differentiation. Cells were plated in micromass culture and were either treated 
(+) or not treated (–) with transforming growth factor β1 (TGFβ1) for 6 days. Aa, 
Representative pictures of Alcian blue stained micromasses (in duplicate). Ab, Stained 
micromasses were extracted with 6M guanidine HCl, and the absorbance of the extracted dye 
was measured at 630 nm. Data are shown as the mean and SD of duplicates. B. Osteogenic 
differentiation. Clonal cell populations in monolayers were either treated (+) or not treated (–) 
with osteogenic medium for 3 weeks. Ba, Representative pictures of Alizarin red stained cells 
(in duplicate). Bb, Quantitation of calcium deposition (expressed as microgram of calcium 
per microgram of protein content, determined in parallel wells). Data are shown as mean and 
SD of triplicates. C. Adipogenic differentiation. Ca, Representative picture of Oil red O-
stained cells upon adipogenic treatment. Cb, Percentage of Oil Red O positive colonies per 
each clone. 
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Supplementary Figure 1. Kinetics of growth of human synovial clonal cell populations. 
Growth in culture is expressed as number of population doublings (PDs) over time (days). 
The clones selected for cell differentiation assays are shown in red. 
 
